plse stock: Pulse Biosciences (PLSE) Guide
PLSE (Pulse Biosciences, Inc.)
plse stock is the NASDAQ ticker symbol for Pulse Biosciences, Inc., a medical technology company developing nano‑pulse stimulation (NPS) and related ablation systems intended for dermatologic, soft‑tissue and cardiac applications. The company’s public listing attracts interest from investors tracking emerging medical‑device innovators and clinical‑stage firms. This article provides a neutral, sourced overview of Pulse Biosciences’ business, technology, trials, financial and stock information, governance, risks and recent developments.
What you’ll learn: who Pulse Biosciences is, how its CellFX and nsPFA technologies work, key clinical and regulatory milestones, how to check the latest plse stock quotes and filings, and where to find official investor resources. For trading, consider using regulated platforms such as Bitget for market access and tools.
Company overview
Pulse Biosciences, Inc. focuses on the development and commercialization of nano‑pulse stimulation (NPS) based medical devices designed to treat a range of dermatologic and soft‑tissue conditions and to explore cardiac ablation applications. Founded in the mid‑2010s and headquartered in the United States, the company’s primary commercial product series has centered on the CellFX system for dermatologic tissue treatments. Pulse positions NPS as a non‑thermal, localized pulsed electric field technology that creates intracellular effects leading to targeted cell elimination while preserving surrounding structural tissue.
Key points
- Ticker: PLSE (NASDAQ)
- Core technology: Nano‑Pulse Stimulation (NPS) / nsPFA (nano‑second Pulsed Field Ablation) for dermatology and procedural medicine
- Flagship product family: CellFX platform (dermatology-focused)
How this relates to plse stock
Investors searching for information on plse stock typically want company background, product status, clinical pipelines, regulatory progress, and financial trends that influence share performance. This article compiles that information with citations to primary public sources such as company investor releases, SEC filings and major financial outlets.
History and corporate timeline
Pulse Biosciences was formed to commercialize nano‑pulse stimulation technologies arising from scientific research in pulsed electric fields. The company’s timeline includes R&D milestones, regulatory interactions, and public listing events:
- 2014–2016 — Foundation and early R&D: Company incorporated and initial NPS research and preclinical development conducted to demonstrate selective cellular effects in dermatologic and soft tissue models.
- Late 2010s — Clinical development: Early clinical studies of the CellFX system for benign skin lesions and dermatologic indications; investigator‑initiated studies and device refinements.
- IPO / Listing: Pulse Biosciences’ common shares began trading on the NASDAQ under the ticker PLSE following its public offering/listing (see company SEC filings for exact dates and offering details).
- 2020s — Product commercialization and pipeline expansion: Commercial launches in targeted dermatologic markets, expanded IDE applications and exploratory programs in cardiac ablation (nsPFA) and percutaneous soft‑tissue ablation.
For exact chronological dates such as IPO listing day and filing submission dates, consult Pulse Biosciences’ SEC filings (Form S‑1/10‑K/10‑Q) and company press releases.
Products and technology
Pulse Biosciences’ technology suite centers on Nano‑Pulse Stimulation (NPS), an electrical pulse‑based modality with specific device implementations for procedural medicine.
Nano‑Pulse Stimulation (NPS) — technical summary
NPS delivers ultra‑short, high‑voltage electric pulses to targeted tissue. These pulses are designed to permeabilize subcellular structures, induce regulated cell death in targeted cells and reduce collateral thermal damage compared with traditional thermal ablation techniques. The mechanism relies on delivering energy in nanoseconds, creating intracellular effects (including apoptosis or other programmed cell death pathways) rather than bulk heating. NPS is categorized as a pulsed electric field therapy class distinct from continuous radiofrequency or microwave ablation.
Flagship device — CellFX System
The CellFX family is Pulse’s marketed system for dermatologic and benign lesion applications. The system includes generators, treatment handpieces/electrodes and workflow software. CellFX is intended to enable clinicians to remove or ablate selected benign skin lesions, warts, and other dermatologic targets with precision and minimal thermal injury. Device variations and handpiece designs are used for different lesion sizes and depths.
nsPFA and cardiac applications
Pulse has explored nano‑second Pulsed Field Ablation (nsPFA) as an approach for cardiac tissue ablation, including atrial fibrillation (AF) applications. nsPFA aims to create durable cardiac tissue isolation with reduced risk of collateral thermal injury to adjacent structures (e.g., esophagus). These programs often proceed through preclinical studies and investigational device exemptions (IDEs) before human safety and efficacy trials.
Product design and safety features
Design emphasis for Pulse devices includes controlled pulse delivery, disposable electrode/handpiece interfaces to maintain sterility, and software‑controlled treatment parameters. Safety testing, biocompatibility checks, and manufacturing quality systems are referenced in regulatory submissions; for specific certifications and quality approvals, refer to the company’s regulatory disclosures.
Product lines and indications
- Dermatology / benign lesions: CellFX handhelds and electrodes for common lesions, warts, seborrheic keratoses, and other benign skin targets.
- Percutaneous electrodes: Needle and probe designs for soft‑tissue ablation and research uses.
- Cardiac ablation tools: Clamp and catheter configurations explored for atrial fibrillation and other electrophysiology indications.
Research and development
Pulse maintains R&D programs aimed at expanding clinical indications for NPS and nsPFA, refining device ergonomics, and validating safety/efficacy data through investigator‑led and sponsor‑led trials. R&D partnerships with academic medical centers and independent investigators are common in device development to generate peer‑reviewed evidence. Ongoing R&D topics include lesion durability, tissue selectivity, optimization of pulse parameters and next‑generation treatment handpiece designs.
Clinical trials and regulatory status
Clinical development and regulatory interactions are central to plse stock’s valuation by market participants. The company has conducted and sponsored clinical trials across dermatologic and procedural indications. Typical regulatory steps include feasibility studies, IDE applications for U.S. investigational use, and 510(k) or PMA pathways depending on device classification.
Major clinical programs
- Dermatology: multi‑center trials evaluating CellFX for removal of benign lesions, with endpoints assessing lesion clearance, healing time, cosmetic outcomes, and device safety.
- Cardiac nsPFA: preclinical and early human studies assessing lesion formation, safety endpoints (e.g., lack of collateral injury), and electrical isolation durability for AF.
As of 2026-01-28, company press releases and clinical trial registries list active or recently completed trials; for exact trial identifiers, enrollment status, and primary endpoints, consult ClinicalTrials.gov and Pulse Biosciences’ investor relations updates.
Market and competitive position
Pulse operates in the medical devices and instruments sector, competing in subsegments for tissue ablation, dermatologic procedural devices, and electrophysiology tools. Competitors include established device manufacturers and emerging startups developing pulsed electric field or alternative ablation technologies. Key market opportunities stem from unmet needs for non‑thermal ablation tools that reduce collateral damage and improve patient recovery in dermatology and cardiac ablation.
Competitive landscape
The competitive set includes companies developing radiofrequency, cryoablation, laser and pulsed‑field technologies. Pulse differentiates by focusing on nano‑pulse timing and specific device designs for dermatologic and procedural uses. Market penetration depends on clinical evidence, regulatory clearances, reimbursement pathways and adoption by clinical specialties (dermatology, electrophysiology, surgical oncology).
Partnerships and collaborations
Pulse engages with academic medical centers, clinical investigators and device research partners to run trials and generate peer‑reviewed data. Public announcements and investor releases list named collaborators and study sites; for the latest partner list and scope, consult company press releases and conference presentations.
Financial information
Pulse Biosciences is a clinical‑stage / early‑commercial medical device company that historically reports revenue from product sales and recognizes research & development and selling, general and administrative expenses that often result in operating losses as the company invests in trials and commercialization. Financial performance for plse stock is available from quarterly (Form 10‑Q) and annual (Form 10‑K) SEC filings and investor presentations.
As of 2026-01-28, for current revenue trends, profitability metrics, cash position and balance sheet items, consult the company’s most recent SEC filings. Public financial pages (e.g., Yahoo Finance, CNBC) provide summarized trailing‑twelve‑month revenue, net income or loss, cash and short‑term investments, and debt details. Always verify key numbers using the primary filings.
Key financial metrics (what to look for)
- Market capitalization: Market cap demonstrates the public valuation of plse stock; varies with share price and outstanding shares.
- Shares outstanding and float: Important for liquidity and dilution considerations.
- Revenue (TTM and quarterly): Indicates commercial traction of CellFX and related product sales.
- Net income / loss and EPS: Reveals profitability; many clinical‑stage device firms report consistent net losses while investing in R&D and commercialization.
- Cash and short‑term investments: Critical for runway; watch operating cash burn versus cash on hand.
- Debt levels: Note any convertible notes or significant liabilities that may affect capital structure.
Each metric has context: market cap reflects market sentiment; cash indicates near‑term liquidity; revenue and EPS show commercial progress. For plse stock, examine trends across consecutive quarters and management guidance given in earnings calls.
Stock information
plse stock trades on the NASDAQ exchange under the symbol PLSE. Typical U.S. market trading hours apply to NASDAQ‑listed securities. Liquidity characteristics (average daily trading volume, float, bid/ask spreads) can be obtained from market data providers and brokerage platforms.
Historical performance
Historical price action for plse stock has been influenced by clinical milestones, product launch announcements, regulatory news, and broader medical‑device sector sentiment. The stock’s volatility reflects event‑driven trading common to small‑to‑mid‑cap clinical‑stage companies. For specifics on 52‑week ranges, historical rallies or drawdowns, use finance portals and the company’s investor relations charts.
Trading and derivatives
Options availability, short interest and derivative instruments for plse stock depend on the liquidity and exchange listing rules. Some NASDAQ‑listed names of similar size may have limited options chains. Short interest figures are published regularly by market data vendors and may be referenced by investors to assess sentiment; check sources such as official exchange reports or major financial data platforms.
Corporate governance and management
Key executives (CEO, CFO, medical and R&D leads) and the board of directors shape strategy, clinical priorities and capital allocation for Pulse. Executive biographies, compensation disclosures and governance policies are described in proxy statements and annual reports filed with the SEC.
When evaluating plse stock from a governance perspective, check for:
- Management experience in medical devices and commercial scaling
- Board independence and relevant clinical expertise
- Shareholder alignment, executive compensation structure and recent board changes
Major shareholders and insider activity
Institutional ownership and insider holdings can provide signals about long‑term investor interest in plse stock. Form 13D/G and Form 4 filings disclose large holders and insider transactions. For up‑to‑date institutional ownership percentages and recent insider buys or sales, consult 13F filings (for institutional managers), SEC Form 4 disclosures and company investor relations announcements.
Analysts, ratings and market sentiment
Coverage of plse stock by sell‑side analysts and independent research houses varies. Analysts publish target prices and ratings based on clinical outcomes, commercialization progress and financial forecasts. Market sentiment often clusters around trial readouts and FDA/IDE announcements. To see consensus ratings or a breakdown of buy/hold/sell recommendations, consult major financial data platforms that aggregate analyst reports.
Legal, regulatory and risk factors
Material risks for Pulse and plse stock are described in the company’s SEC filings (Risk Factors section of Form 10‑K and 10‑Q). Common device‑company risks include:
- Clinical trial failure or delays that affect regulatory approvals and market access.
- Regulatory setbacks or adverse interactions with agencies (e.g., FDA) that may delay commercialization.
- Manufacturing or quality system issues that could lead to recalls or enforcement actions.
- Competitive pressure from other ablation technologies or new entrants.
- Capital‑raising needs and dilution risk if cash reserves are insufficient to fund operations.
- Product liability or litigation risks inherent to medical devices.
As of 2026-01-28, review the most recent 10‑K/10‑Q for a current and exhaustive list of disclosed risks affecting plse stock.
Recent news and notable events
Investors tracking plse stock monitor press releases, conference presentations (e.g., medical and investor conferences), clinical trial milestones (enrollment completions, primary endpoint announcements), IDE/510(k)/PMA interactions and quarterly earnings calls. Below are typical categories of news to watch; confirm dates and specifics in primary sources.
- Clinical milestone announcements (e.g., successful trial cohort results or safety reports).
- Regulatory submissions or IDE approvals allowing human trials.
- Product launches, commercial distribution agreements or reimbursement updates.
- Scientific publications or presentations at peer‑reviewed conferences.
- Financial earnings releases and management guidance.
As an example of how to reference sources with dates: As of 2026-01-28, major finance portals such as Yahoo Finance and CNBC provide live quotes and summarize recent news headlines for PLSE; specific corporate announcements with dates are available from Pulse Biosciences’ investor relations releases and SEC filings.
Corporate social responsibility and ethics
Pulse highlights clinical trial ethics, patient safety, and quality systems in governance materials. Any ESG initiatives, community programs or manufacturing quality certifications will be noted in sustainability or investor disclosures; consult the company’s corporate responsibility statements for current programs.
See also
- Medical devices industry overview
- Ablation technologies and pulsed electric field therapies
- NASDAQ listed medical device companies and regulatory pathways
References and primary sources
Primary and authoritative sources for verifying information about plse stock include:
- Pulse Biosciences official investor relations releases and presentations
- SEC filings (Form 10‑K, 10‑Q, 8‑K, S‑1, proxy statements, Form 4)
- Clinical trial registries (e.g., ClinicalTrials.gov) for trial identifiers and status
- Major financial news outlets and market quote pages (e.g., Yahoo Finance, CNBC, Nasdaq quote pages) for live market data and summarized metrics
As of 2026-01-28, specific reporting on plse stock and Pulse Biosciences by outlets such as Yahoo Finance, CNBC, and Nasdaq is available; for exact quotes, market cap figures and recent headlines, consult those sources directly and confirm against SEC filings for material corporate events.
External links
Official resources to consult for the most accurate, current information on plse stock and Pulse Biosciences include the company’s investor relations page and the SEC filings repository. Financial quote pages and clinical trial registries provide supplementary market and trial‑status data.
How to follow plse stock and next steps
If you want to track plse stock in real time, consider these steps:
- Subscribe to Pulse Biosciences investor alerts and review SEC filings promptly after release.
- Monitor clinical trial registries for enrollment status and primary endpoint announcements that may move the stock.
- Use market data platforms for live quotes, average volume and options availability; verify figures against multiple providers.
- For trading access and tools, consider regulated platforms such as Bitget which offer market data and order execution—always confirm available instruments and regional availability.
Remember: this article is a neutral informational overview and is not investment advice. For investment decisions about plse stock, consult licensed financial professionals and perform your own due diligence using primary filings and up‑to‑date market data.
Further explore case studies, regulatory filings and real‑time market data to form a complete view of plse stock. To trade or monitor equities and derivatives with an integrated platform, consider checking Bitget’s trading features for NASDAQ‑listed instruments.
